Involvement of transmitters in pituitary adenylate cyclase-activating polypeptide-induced hyperthermia

Regul Pept. 2003 Oct 15;115(3):187-93. doi: 10.1016/s0167-0115(03)00173-3.

Abstract

The involvement of transmitters in the hyperthermic effect of centrally administered pituitary adenylate cyclase-activating polypeptide (PACAP-38) was studied. Rats were treated with different receptor antagonists or agonists in doses that per se proved to be ineffective. The following agonists and antagonists were used: haloperidol, phenoxybenzamine, propranolol, atropine, bicuculline, naloxone, apomorphine, bromocriptine and methysergide. Apomorphine and bromocriptine enhanced the elevation of body temperature induced by PACAP-38. The PACAP-38-hyperthermia was antagonized by haloperidol while other receptor blockers used were ineffective. Our results suggest that dopaminergic but not cholinergic, noradrenergic, serotoninergic, GABA-ergic or opioid mediation may be involved in the hyperthermic effect of PACAP-38 in rats.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apomorphine / pharmacology
  • Body Temperature / drug effects
  • Bromocriptine / pharmacology
  • Dopamine Antagonists / pharmacology
  • Dose-Response Relationship, Drug
  • Fever / chemically induced
  • Fever / physiopathology*
  • Haloperidol / pharmacology
  • Male
  • Neuropeptides
  • Neurotransmitter Agents / agonists
  • Neurotransmitter Agents / antagonists & inhibitors
  • Neurotransmitter Agents / physiology*
  • Pituitary Adenylate Cyclase-Activating Polypeptide
  • Rats
  • Rats, Wistar
  • Time Factors

Substances

  • Adcyap1 protein, rat
  • Dopamine Antagonists
  • Neuropeptides
  • Neurotransmitter Agents
  • Pituitary Adenylate Cyclase-Activating Polypeptide
  • Bromocriptine
  • Haloperidol
  • Apomorphine